Detail akcie Molecular Partn N online

Business Summary: Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Molecular Partners AG revenues decreased from SF5M to SF0K. Net loss increased 14% to SF49M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest Income - Non Bank decrease of 87% to SF366K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -SF1.29 to -SF1.33.